PPreplord UPSCAn IIT Alumni Initiative

UPSC Prelims GS1 2022 Question 39: Vaccines (Types)

General Science & Technology › Biotechnology & Health Technology › Vaccines • Concept: Types — Vaccines • Marking: +2.0 / −0.667

UPSC GS1 2022 • Q39General Science & TechnologyVaccinesTypes

In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements : Which of the statements given above are correct?

  • 1. The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform.
  • 2. Sputnik V vaccine is manufactured using vector based platform.
  • 3. COVAXIN is an inactivated pathogen based vaccine.

Official Answer & Detailed Explanation

Verified Answer: (B) 2 and 3 only
Covishield and Covaxin were the first vaccines permitted to be administered to people in India in the first half of 2021. Sputnik came weeks later. Covishield: It is not an mRNA-based vaccine. Covishield (produced by Serum Institute of India) is a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike (S) glycoprotein. Following administration, the genetic material of part of corona virus is expressed which stimulates an immune response. Hence statement 1 is not correct. By using elimination technique, one can reach option (b). Hence option (b) is the correct answer. Covaxin: It is an indigenous, inactivated pathgen type vaccine developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility. The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Hence statement 3 is correct. Sputnik V: It is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health. Hence statement 2 is correct.

Option-by-Option Breakdown

Option (A) — Eliminated
1 and 2 only
Option (B) — Correct Answer
2 and 3 only
Option (C) — Eliminated
1 and 3 only
Option (D) — Eliminated
1, 2 and 3

UPSC Prelims Topic Weightage & Syllabus Context (2011–2026)

Vaccines under General Science & Technology has appeared 4 times in UPSC CSE Prelims GS1 between 2021–2026. Practicing all PYQs from this topic in timed batches helps build pattern recognition and cuts down negative-marking traps.

Frequently Asked Questions

What is the correct answer to UPSC Prelims GS1 2022 Question 39?
The officially verified correct answer is Option (B): 2 and 3 only.
Which UPSC Prelims syllabus topic does GS1 2022 Q39 belong to?
This question is categorized under General Science & Technology (Biotechnology & Health Technology) → Vaccines → Types. Across 2011–2026, UPSC has asked 4 PYQs from this topic.
What is the marking scheme and ideal time for this UPSC GS1 question?
UPSC GS Paper 1 awards +2.0 marks for a correct answer and deducts 0.667 marks for an incorrect attempt. Aim to solve this question within 72 seconds.

Related UPSC GS1 PYQs on Vaccines